Cargando…

Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia

The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Komissarov, Alexey A., Kislova, Maria, Molodtsov, Ivan A., Petrenko, Andrei A., Dmitrieva, Elena, Okuneva, Maria, Peshkova, Iuliia O., Shakirova, Naina T., Potashnikova, Daria M., Tvorogova, Anna V., Ptushkin, Vadim V., Efimov, Grigory A., Nikitin, Eugene A., Vasilieva, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820366/
https://www.ncbi.nlm.nih.gov/pubmed/36613860
http://dx.doi.org/10.3390/ijms24010416
_version_ 1784865449011314688
author Komissarov, Alexey A.
Kislova, Maria
Molodtsov, Ivan A.
Petrenko, Andrei A.
Dmitrieva, Elena
Okuneva, Maria
Peshkova, Iuliia O.
Shakirova, Naina T.
Potashnikova, Daria M.
Tvorogova, Anna V.
Ptushkin, Vadim V.
Efimov, Grigory A.
Nikitin, Eugene A.
Vasilieva, Elena
author_facet Komissarov, Alexey A.
Kislova, Maria
Molodtsov, Ivan A.
Petrenko, Andrei A.
Dmitrieva, Elena
Okuneva, Maria
Peshkova, Iuliia O.
Shakirova, Naina T.
Potashnikova, Daria M.
Tvorogova, Anna V.
Ptushkin, Vadim V.
Efimov, Grigory A.
Nikitin, Eugene A.
Vasilieva, Elena
author_sort Komissarov, Alexey A.
collection PubMed
description The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus. We found that vaccination of the COVID-19–recovered individuals resulted in the boosting of pre-existing immune responses in both healthy donors and CLL patients. However, the COVID-19–naïve CLL patients demonstrated a considerably lower antibody response than the healthy donors, although they developed a robust T cell response. Regardless of the previous infection, the individuals over 70 years old demonstrated a decreased response to vaccination, as did those receiving anti-CD20 therapy. In summary, we showed that Sputnik V, like other vaccines, did not induce a robust antibody response in individuals with CLL; however, it provided for the development of a significant anti-COVID-19 T cell response.
format Online
Article
Text
id pubmed-9820366
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98203662023-01-07 Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia Komissarov, Alexey A. Kislova, Maria Molodtsov, Ivan A. Petrenko, Andrei A. Dmitrieva, Elena Okuneva, Maria Peshkova, Iuliia O. Shakirova, Naina T. Potashnikova, Daria M. Tvorogova, Anna V. Ptushkin, Vadim V. Efimov, Grigory A. Nikitin, Eugene A. Vasilieva, Elena Int J Mol Sci Article The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus. We found that vaccination of the COVID-19–recovered individuals resulted in the boosting of pre-existing immune responses in both healthy donors and CLL patients. However, the COVID-19–naïve CLL patients demonstrated a considerably lower antibody response than the healthy donors, although they developed a robust T cell response. Regardless of the previous infection, the individuals over 70 years old demonstrated a decreased response to vaccination, as did those receiving anti-CD20 therapy. In summary, we showed that Sputnik V, like other vaccines, did not induce a robust antibody response in individuals with CLL; however, it provided for the development of a significant anti-COVID-19 T cell response. MDPI 2022-12-27 /pmc/articles/PMC9820366/ /pubmed/36613860 http://dx.doi.org/10.3390/ijms24010416 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Komissarov, Alexey A.
Kislova, Maria
Molodtsov, Ivan A.
Petrenko, Andrei A.
Dmitrieva, Elena
Okuneva, Maria
Peshkova, Iuliia O.
Shakirova, Naina T.
Potashnikova, Daria M.
Tvorogova, Anna V.
Ptushkin, Vadim V.
Efimov, Grigory A.
Nikitin, Eugene A.
Vasilieva, Elena
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
title Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
title_full Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
title_fullStr Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
title_full_unstemmed Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
title_short Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
title_sort coronavirus-specific antibody and t cell responses developed after sputnik v vaccination in patients with chronic lymphocytic leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820366/
https://www.ncbi.nlm.nih.gov/pubmed/36613860
http://dx.doi.org/10.3390/ijms24010416
work_keys_str_mv AT komissarovalexeya coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT kislovamaria coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT molodtsovivana coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT petrenkoandreia coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT dmitrievaelena coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT okunevamaria coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT peshkovaiuliiao coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT shakirovanainat coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT potashnikovadariam coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT tvorogovaannav coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT ptushkinvadimv coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT efimovgrigorya coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT nikitineugenea coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia
AT vasilievaelena coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia